How do I convert a patient taking Mixtard (insulin) 30 units in the morning and 35 units in the evening to a basal-bolus regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting Mixtard 30/35 Units to Basal-Bolus Insulin Regimen

Calculate the total daily dose (65 units) and split it 50% basal insulin (approximately 30-35 units of long-acting insulin once daily) and 50% prandial insulin (approximately 10-12 units of rapid-acting insulin before each of three meals), then titrate based on glucose monitoring. 1

Step 1: Calculate Total Daily Dose and Initial Split

Current total daily insulin dose = 30 + 35 = 65 units total 1

For conversion from premixed insulin to basal-bolus therapy:

  • Give 50% as basal insulin (long-acting): 32-33 units once daily 1
  • Give 50% as prandial insulin (rapid-acting): Divide remaining 32-33 units among three meals = approximately 10-11 units before each meal 1

The American Diabetes Association recommends this 50:50 split when transitioning from premixed insulin regimens to basal-bolus therapy 1. Randomized trials demonstrate that basal-bolus therapy provides superior glycemic control with reduced hospital complications compared to premixed insulin regimens 1.

Step 2: Select Specific Insulin Products

Basal insulin options:

  • Insulin glargine (Lantus/Basaglar): 32-33 units once daily, typically in evening 1
  • Insulin detemir: May require 38% higher total daily dose than glargine (approximately 44-46 units), often split twice daily 1
  • Insulin degludec (Tresiba): 32-33 units once daily 2

Prandial insulin:

  • Rapid-acting analog (insulin aspart/lispro/glulisine): 10-11 units before each of three meals 1, 3

Step 3: Titration Protocol

Basal Insulin Titration:

  • Target fasting glucose: 80-130 mg/dL 1, 3
  • If fasting glucose 140-179 mg/dL: Increase basal insulin by 2 units every 3 days 1, 3
  • If fasting glucose ≥180 mg/dL: Increase basal insulin by 4 units every 3 days 1, 3
  • If hypoglycemia occurs: Reduce dose by 10-20% immediately 1, 3

Prandial Insulin Titration:

  • Target 2-hour postprandial glucose: <180 mg/dL 3, 2
  • Increase each meal's dose by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings 1, 3, 2
  • Adjust each meal dose independently based on glucose 2 hours after that specific meal 3

Step 4: Monitoring Requirements

Essential glucose checks:

  • Fasting glucose every morning to guide basal insulin adjustments 1, 3
  • Pre-meal glucose before each meal to assess basal insulin adequacy 3, 2
  • 2-hour postprandial glucose after meals to guide prandial insulin titration 3, 2

Step 5: Critical Threshold Warning

Watch for overbasalization when basal insulin exceeds 0.5 units/kg/day (approximately 35-40 units for a 70-80 kg patient) 1, 4. Clinical signals include:

  • Basal dose >0.5 units/kg/day 1
  • Bedtime-to-morning glucose differential ≥50 mg/dL 1
  • Hypoglycemia episodes 1
  • High glucose variability 1

When basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, intensify prandial insulin rather than continuing to escalate basal insulin alone 1, 4.

Step 6: Medication Management

Continue metformin unless contraindicated when initiating basal-bolus therapy, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain 1. Consider discontinuing sulfonylureas when advancing to basal-bolus insulin to prevent hypoglycemia 1.

Common Pitfalls to Avoid

  • Never continue premixed insulin (Mixtard) in patients transitioning to basal-bolus therapy, as randomized trials show significantly increased hypoglycemia rates with premixed regimens 1
  • Never delay insulin intensification in patients not achieving glycemic goals, as this prolongs hyperglycemia exposure and increases complication risk 1
  • Never use sliding scale insulin as monotherapy during the transition, as this leads to dangerous glucose fluctuations 1, 2
  • Never give rapid-acting insulin at bedtime to avoid nocturnal hypoglycemia risk 1, 2

Patient Education Essentials

Provide comprehensive education on:

  • Proper insulin injection technique with 90-degree angle and systematic site rotation 2
  • Recognition and treatment of hypoglycemia with 15 grams of fast-acting carbohydrate 1, 3
  • Self-monitoring of blood glucose technique 1, 2
  • "Sick day" management rules 1
  • Insulin storage and handling 1

Expected Timeline and Outcomes

  • Fasting glucose should reach 80-130 mg/dL within 2-4 weeks of basal insulin titration 2
  • Postprandial glucose should improve to <180 mg/dL within 4-6 weeks of prandial insulin optimization 2
  • HbA1c should decrease by 1-2% within 3 months with optimized basal-bolus therapy 2
  • Total daily insulin requirements will likely stabilize at 0.5-1.0 units/kg/day once proper distribution is achieved 2

References

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Insulin Regimen Intensification Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Insulin Regimen Adjustment for Persistent Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is a reasonable approach to writing a regimen for mealtime insulin and basal insulin?
What is the proper protocol for using sliding scale insulin (SSI) in patients with hyperglycemia?
What are the basal insulin dosing guidelines for a 70-kilogram patient with diabetes?
When to use a fixed dose versus an insulin sliding scale for glucose management?
How do you calculate insulin doses?
What are the treatment options for an adult patient with no significant medical history presenting with a mild to moderate rash?
What are the potential causes and management options for a patient with a chronic cough, considering underlying conditions such as gastroesophageal reflux disease (GERD), asthma, chronic obstructive pulmonary disease (COPD), and infections, particularly in those with a history of smoking or exposure to environmental toxins?
What is the diagnostic approach for an adult patient with no prior medical history presenting with bilateral leg edema?
What is the best course of action for a 45-year-old female patient with recurrent urinary tract infection (UTI) symptoms, negative urine culture, and low urine pH (< 5), despite previous urine tests?
What is the recommended treatment approach for a patient with HER2 (Human Epidermal growth factor Receptor 2)-positive breast cancer using Neoadjuvant HER2 therapy?
What is the recommended antibiotic (abx) therapy for a patient with lung cancer receiving chemotherapy (chemo) who presents with a cold and is at risk for healthcare-associated pneumonia (HCAP)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.